ArticleAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists2026
Evaluating treatment effectiveness: Complementing RCTs with real-world data.
Article in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWhile randomized controlled trials remain the gold standard for assessing treatment efficacy, studies using real-world data (RWD) offer valuable insights into treatment effectiveness across broader, more diverse patient populations. This commentary explores the importance of using fit-for-purpose data and emphasizes the need for rigorous evaluation of RWD quality to support valid and actionable evidence generation. SUMMARY: The utility of RWD-based studies depends heavily on the fitness-for-purpose of the data source, which requires careful assessment of 5 key quality dimensions: relevance, extensiveness, timeliness, coherence, and reliability. Practical examples from coronavirus disease 2019 (COVID-19) comparative effectiveness research are used to illustrate each data quality domain.
conclusionsAs the need for RWD increases, especially for post-COVID-19 pandemic decision-making, ensuring high data quality and appropriate study design is critical. Proper evaluation of RWD sources enhances the credibility of findings and supports their use in meta-analyses, clinical guidelines, and healthcare policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.